Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
IPHA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Innate Pharma S.A.NASDAQ: IPHA
Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025
Selling, general & admin declines year over year
Q4 FY2025 selling, general & admin of €1.23M fell 47.6% year over year. Over 3 fiscal years it compounded at -8.7% a year.
Context
- Selling, general & admin amounted to 394.7% of revenue in FY2025, up 300.1 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of €75.88M (+589.9%) for the fiscal year ending Dec 2026, a step up from the -7.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- €1.23M— QoQ
- Last fiscal yearDec 2025
- €11M-7.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
EUR · from the income statement
- Latest · FY2025
- 11M EUR
- Year-over-year change
- -7.8%
- 4-year CAGR
- -19.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11M | -7.8% |
| FY2024 | 2024-12-31 | 11.93M | +1.6% |
| FY2023 | 2023-12-31 | 11.75M | -18.8% |
| FY2022 | 2022-12-31 | 14.47M | -43.3% |
| FY2021 | 2021-12-31 | 25.52M | — |
Selling, General & Admin vs competitors
How IPHA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.8% is the 8th highest of 9, against a peer median of -4.1%.
- Selling, general & admin amounts to 394.7% of revenue for IPHA, versus a peer median of 1276.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $9.69M USD | +36.8% | +16.2% | — | |
| LTM Mar 2026 | $9.36M USD | -6.3% | -5.7% | 12.9% | |
| Peer median (excluding IPHA) | — | -4.1% | -6.2% | 1276.2% | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.11M | 57.67M | 51.9M | 12.62M | 2.79M |
| Cost of Revenue | 47M | 51.66M | 56.02M | 51.98M | 0 |
| Gross Profit | (22.3M) | 6.01M | 5.62M | 12.62M | 2.79M |
| Gross Margin | -184.1% | 10.4% | 10.8% | 100.0% | 100.0% |
| Research & Development | 47M | 51.66M | 56.02M | 51.98M | 43.62M |
| Selling, General & Admin | 25.52M | 14.47M | 11.75M | 11.93M | 11M |
| Operating Expenses | 25.52M | 63.44M | 18.29M | 64.2M | 56.21M |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| EBITDA | (43.23M) | (12.28M) | (1.84M) | (46.91M) | (43.65M) |
| EBITDA Margin | -356.9% | -21.3% | -3.5% | -371.7% | -1566.1% |
| Operating Income | (47.83M) | (57.43M) | (12.67M) | (51.58M) | (53.43M) |
| Operating Margin | -394.9% | -99.6% | -24.4% | -408.6% | -1916.9% |
| Interest Income | 327K | 546K | 3.18M | 2.44M | 1.32M |
| Interest Expense | 312K | 288K | 640K | 566K | 440K |
| Other Income / Expenses | 2.35M | (547K) | 5.1M | 2.1M | 4.25M |
| Income Before Tax | (45.48M) | (57.97M) | (7.57M) | (49.47M) | (49.18M) |
| Pre-Tax Margin | -375.5% | -100.5% | -14.6% | -392.0% | -1764.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Net Margin | -436.0% | -100.7% | -14.6% | -392.0% | -1764.5% |
| EPS (Basic) | (0.57) | (0.73) | (0.09) | (0.61) | (0.53) |
| EPS (Diluted) | (0.57) | (0.73) | (0.09) | (0.61) | (0.53) |
| Weighted Avg Shares | 79.54M | 79.59M | 84.11M | 81.05M | 89.42M |
| Weighted Avg Shares (Diluted) | 79.54M | 79.64M | 84.11M | 81.05M | 89.42M |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.